AMARIN CORP PLC\UK
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
United Kingdom
Country
Ireland
Business Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2, ,
Mailing Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2, ,
Phone
353 1 6699 020
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$38.80M
Net Income
$211.49M
Total Liabilities
$595.33M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Successful global expansion into 7 new markets, diversifying revenue streams through an asset-light out-licensing strategy.
- Advancing pipeline with a new Phase 2 trial for Vascepa (AMR101) and targeting two new indications by 2026, potentially unlocking an estimated $500 million in annual market opportunity.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.